Possibilities of gene therapies for cancer

Annals of Medicine

Volumn 29, Issue 1, 1997, Pages 1-4

  Lashford, Linda S ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRODRUG;

CANCER; CANCER CHEMOTHERAPY; EDITORIAL; EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; GENETIC MANIPULATION; GENETIC REGULATION; HOST RESISTANCE; IMMUNOTHERAPY; PRIORITY JOURNAL; TUMOR CELL;

EID: 0031018203     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899708998737     Document Type: Editorial

References (36)

1. Miller DG, Adam MA, Miller AD. Gene transfer by retroviral vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-42.
2. Welsh RM, Cooper NR, Jensen FC, Oldstone MBA. Human serum lyses RNA tumour viruses. Nature 1975; 257: 612-4.
3. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumours. Science 1992; 256: 1550-2.
4. Raffel C, Culver K, Kohn D, et al. Gene therapy for the treatment of recurrent paediatric malignant astrocytomas with in vivo tumour transduction with the herpes simplex thymidine kinase gene/gancyclovir system. Hum Gene Ther 1994; 5: 863-90.
5. Takeuchi Y, Cosset FL, Lachmann PJ, et al. Type C retrovirus inactivation by complement is determined by both the viral genome and the producer cell. J Virol 1994; 68: 8001-7.
6. Wagner E, Zatloukal K, Cotten M. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor mediated gene delivery and expression of transfected genes. Proc Nat Acad Sci USA 1992; 89: 6099-103.
7. Lebrowski JS, McNally M, Okarma TB, et al. Adeno associated viruses: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types. Mol Cell Biol 1988; 8: 3988-97.
8. Latchman DS. Herpes simplex virus vectors for gene therapy. Mol Biotechnol 1994; 2: 179-98.
9. Kramer EJ, Perricaudet M. Adenovirus and adenoassociated virus mediated gene transfer. Br Med Bull 1995; 51: 31-44.
10. Crystal RG. Administration of an adenovirus containing the human CFTR CDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-50.
11. Yang Y, Nunes FA, Berensci K, et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-9.
12. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996; 217: 11-22.
13. Viquin JT, Guerette B, Kinoshita I, et al. FK506 immuno-suppression to control the immune reactions triggered by first generation adenovirus mediated gene transfer. Hum Gene Ther 1995; 6: 1391-401.
14. Hay JG, McElvaney NG, Herena J, Crystal RG. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR and DNA adenovirus gene transfer vector. Hum Gene Ther 1995; 6: 1487-96.
15. Escudier B, Farace F, Angevin E, et al. Immunotherapy with interleukin 2 (IL-2) and lymphokine activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL-2. Eur J Cancer 1994; 30A: 1078-83.
16. Tartour E, Mathiot C, Fridman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992; 46: 473-84.
17. Cayeux S, Beck C, Aicho A, Dorkin B, Blakenskin T. Tumour cells cotransfected with interleukin 7 and B7.1 genes induce CD25 and CD28 on tumour infiltrating lymphocytes and are strong vaccines. Eur J Immunol 1995; 25: 2325-31.
18. Miller AR, McBride WH, Hunt K, Economou JS. Cytokine mediated gene therapy for cancer. Ann Surg Oncol 1994; 1: 436-50.
19. Hock H, Dorsch M, Kunzerdurf U, et al. Vaccinations with tumour cells genetically engineering to produce different cytokines; effectively not superior to a classical adjuvant. Cancer Res 1993; 53: 714-6.
20. Drannoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific and long lasting anti-tumour immunity. Proc Nat Acad Sci USA 1993; 90: 3539-43.
21. Pappo I, Tahara H, Bobbins PD, Gately K, et al. Administration of systemic or local IL2 enhances the anti tumour effects of interleukin-12 gene therapy. J Surg Res 1995; 38: 218-26.
22. Ogasawara M, Rosenberg SA. Enhanced expression of HLA molecules and stimulation of autologous human tumours infiltrating lymphocytes following transduction of melanoma cells with gamma interferon genes. Cancer Res 1993; 53: 3561-8.
23. Faulds D, Heal RC. Gancyclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infection. Drugs 1990; 39: 5997-6331.
24. Freeeman SM, Abboud CN, Whartenby KA, et al. The 'bystander effect': tumour regression when a fraction of the tumour mass is genetically modified. Cancer Res 1993; 53: 5274-83.
25. Vile RG, Nelson JA, Castlden S, Chung H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-tk gene involves an immune component. Cancer Res 1994; 54: 6228-34.
26. Vile RG, Diaz RM, Miller N, et al. Tissue specific gene expression from MO-MLV retroviral vectors with hybrid LTR's containing the murine tyrosinase enhancer/ promoter. Virology 1995; 214: 307-13.
27. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumour specific gene therapy. Hum Gen Ther 1995; 6: 881-93.
28. Wills KN, Huang WM, Harris MP, et al. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Tner 1995; 2: 191-7.
29. Mickisch GH, Aksentijevich I, Schoenlein PV, et al. Transplantation of bone marrow cells from transgenic mice expressing the tumour MDRI gene results in long term protection against the myelosuppressive effect of chemotherapy in mice. Blood 1992; 79: 1087-93.
30. 6 alkylguanine DNA alkyltransferase. Blood 1996; 87: 1957-61.
31. Szilvassy SJ, Fraser CC, Eaves CJ, et al. Retrovirus mediated gene transfer to purified haemopoietic stem cells with long term lympho myelopoietic repopulating ability. Proc Nat Acad Sci USA 1989; 86: 8798-802.
32. Luskey BD, Rosenblatt M, Zsebo K, Williams DA. Stem cell factor, interleukin-3 and interleukin-4 promote retroviral mediated gene transfer into murine haemopoietic stem cells. Blood 1992; 801: 396-402.
33. Mercer WE, Sheilds MT, Lin D. Growth suppression induced by wild type p53 protein is accompanied by selective down regulation of proliferatin-cell nuclear antigen in colon carcinoma cell lines that express c-myc. Cancer Res 1991; 52: 2897-901.
34. Shirasawa B, Furusa M, Yokoyama N, Sasazubi T. Altered growth of human colon cancer cell lines disrupted at actives k-ras. Science 1993; 260: 85-8.
35. Skulling JS, Squatrito RC, Conner JP, Niemann T, Butler RE. p53 gene mutation analysis and antisense mediated growth inhibition of human ovarian carcinoma cell lines. Gynaecol Oncol 1996; 60: 72-80.
36. Meriola D, Cohen JS. Antisense approaches to cancer gene therapy. Cancer Gene Ther 1995; 2: 47-59.